%PDF-1.4
%
73 0 obj
<>
endobj
70 0 obj
<>
endobj
134 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-29T11:54:41Z
2024-03-28T05:54:01-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T05:54:01-07:00
application/pdf
Heather
201019 aug
uuid:13f3d46c-1dd2-11b2-0a00-3809277d8900
uuid:13f3d470-1dd2-11b2-0a00-d30000000000
endstream
endobj
59 0 obj
<>
endobj
60 0 obj
<>
endobj
74 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
22 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
35 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
38 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
41 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
44 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
164 0 obj
[168 0 R]
endobj
165 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.0249 Tw 8 0 0 8 57 714.5293 Tm
[(52.)-875 (Durie FH, )54.8 (Aruf)17.8 (fo )54.8 (A, Ledbetter J, et al. )54.8 (Antibody to the ligand of)]TJ
2.175 -1.25 Td
(CD40, gp39, blocks the occurrence of the acute and chronic forms)Tj
-0.00011 Tc 0 -1.25 TD
(of graft-vs-host disease. J Clin Invest 1994;94:1333-8.)Tj
-2.175 -1.25 Td
[(53.)-875.1 (Grewal IS, Foellmer HG, Grewal KD, et al. Requirement for CD40)]TJ
0 Tc 2.175 -1.25 Td
[(ligand in costimulation induction, )17.8 (T)-257.2 (cell activation, and)]TJ
T*
[(experimental aller)17.8 (gic encephalomyelitis. Science 1996;273:1864-7.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(54.)-875.1 (Gerritse K, Laman JD, Noelle RJ, et al. CD40-CD40 ligand)]TJ
0 Tc 2.175 -1.25 Td
[(interactions in experimental aller)17.8 (gic encephalomyelitis and multiple)]TJ
-0.00011 Tc T*
[(sclerosis. Proc Natl )54.8 (Acad Sci USA)-220.2 (1996;93:2499-504.)]TJ
0 Tc 30.825 10 Td
[(55.)-875 (Mach F)79.8 (, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand)]TJ
2.175 -1.25 Td
(is expressed on human vascular endothelial cells, smooth muscle)Tj
T*
(cells, and macrophages: Implications for CD40-CD40 ligand)Tj
-0.00011 Tc T*
[(signaling in atherosclerosis. Proc Natl )54.8 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1997;94:1931-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(56.)-875.1 (Berner B, )17.7 (W)79.7 (olf G, Hummel KM, Muller GA, Reuss-Borst MA.)]TJ
2.175 -1.25 Td
[(Increased expression of CD40 ligand \(CD154\) on CD4+ )17.7 (T)-257.3 (cells as)]TJ
0 Tc T*
[(a marker of disease activity in rheumatoid arthritis. )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(2000;59:190-5.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
0.02499 Tw 8 0 0 8 54.5 36.791 Tm
(Kitagawa, et al: IFN-)Tj
/T1_0 1 Tf
0 Tw 8 0 1.7005 8 124.4223 36.791 Tm
(\002)Tj
/TT1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 129.9094 36.791 Tm
(induces IL-12 in RA)Tj
0 Tc 0 Tw 51.5113 -0.1321 Td
(1771)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 59.08 407.5 -10.83 re
f*
0.5 w
102.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_1 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
81 0 obj
<>
endobj
117 0 obj
<>
endobj
139 0 obj
<>
endobj
87 0 obj
<>
endobj
78 0 obj
<>
endobj
77 0 obj
<>
endobj
107 0 obj
<>stream
HVpTι&"ApDL7B
$.yHL)LF0c*XXJJ rTQZ" KF2@TD(݄8'ܳ@;BA2{NPуұ%
įJjP%
,Q9iyFp9巪Obsem>*(:VQY=KgWj˳K$:FUWEȷJVw(?M+I}+